Clinical Trials
14 trialsNCT04364178 2026-05-27
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
Stanford University
Phase 1/2 Terminated
NCT06256484 2026-03-11
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Phase 1 Terminated
NCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT03769467 2024-11-14
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Atara Biotherapeutics
Phase 1/2 Terminated
NCT02875613 2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
University of California, San Diego
Phase 2 Terminated
NCT05305040 2024-05-16
Prevent
AlloVir
Phase 2/3 Terminated
NCT03283826 2024-02-23
EMBOLD
Atara Biotherapeutics
Phase 1/2 Terminated
NCT03682055 2023-08-15
Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Cullinan Therapeutics Inc.
Phase 1/2 Terminated
NCT02874651 2022-01-11
ADVANCE
Sun Yat-sen University
Phase 2 Terminated
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT02763254 2019-03-26
CIVIC
Cell Medica Ltd
Phase 2 Terminated
NCT01948180 2019-03-13
CITADEL
Cell Medica Ltd
Phase 2 Terminated